Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.

ARCT

Arcturus Therapeutics (ARCT)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ARCT
DataOraFonteTitoloSimboloCompagnia
06/03/202522:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
24/02/202522:01Business WireArcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025NASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/02/202514:30PR Newswire (US)European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineNASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/02/202514:00Business WireEuropean Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineNASDAQ:ARCTArcturus Therapeutics Holdings Inc
04/02/202514:30Business WireArcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair DesignateNASDAQ:ARCTArcturus Therapeutics Holdings Inc
31/01/202509:00Business WireMeiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19NASDAQ:ARCTArcturus Therapeutics Holdings Inc
30/01/202522:01Business WireArcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
10/01/202514:00Business WireArcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine TrialNASDAQ:ARCTArcturus Therapeutics Holdings Inc
06/01/202522:01Business WireArcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:ARCTArcturus Therapeutics Holdings Inc
18/12/202422:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
16/12/202422:01Business WireArcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
26/11/202422:01Business WireArcturus Therapeutics to Attend Upcoming Investor ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
19/11/202402:00Business WireArcturus Therapeutics to Present at Jefferies London Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/11/202407:00Business WireMeiji Seika Pharma Announces Investment in ARCALIS, Inc.NASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/11/202422:01Business WireArcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical TrialNASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/11/202422:01Business WireArcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
31/10/202421:01Business WireArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
30/09/202414:00PR Newswire (US)Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-VaccinationNASDAQ:ARCTArcturus Therapeutics Holdings Inc
13/09/202414:15PR Newswire (US)Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika PharmaNASDAQ:ARCTArcturus Therapeutics Holdings Inc
13/09/202414:00Business WireJapan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika PharmaNASDAQ:ARCTArcturus Therapeutics Holdings Inc
03/09/202414:30Business WireArcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
27/08/202423:00Business WireArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/08/202422:50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/08/202422:01Business WireArcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
01/08/202422:01Business WireArcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
19/07/202401:30Business WireArcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
17/07/202423:27Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ARCTArcturus Therapeutics Holdings Inc
01/07/202422:01Business WireArcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) ProgramsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
20/06/202414:00Business WireArcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of DirectorsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/06/202416:30Business WireArcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ARCT

La tua Cronologia

Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network